Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in patients with relapsed or refractory neuroblastoma. Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG toget...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: DuBois, Steven G., Chesler, Louis, Groshen, Susan, Hawkins, Randall, Goodarzian, Fariba, Shimada, Hiroyuki, Yanik, Greg, Tagen, Michael, Stewart, Clinton, Mosse, Yael P., Maris, John M., Tsao-Wei, Denice, Marachelian, Araz, Villablanca, Judith G., Matthay, Katherine K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6814395/
https://ncbi.nlm.nih.gov/pubmed/22421195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3201
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg